At its Oct. 9 H1 2026 results briefing, Bloomage BioTechnology said it is expanding beyond its hyaluronic acid strength into PDRN/PN, recombinant collagen, human milk oligosaccharides (HMOs), ergothioneine and salidroside. Some of those new bioactive

2026-10-09

At its Oct. 9 H1 2026 results briefing, Bloomage BioTechnology said it is expanding beyond its hyaluronic acid strength into PDRN/PN, recombinant collagen, human milk oligosaccharides (HMOs), ergothioneine and salidroside. Some of those new bioactives have entered commercialization and have begun to contribute revenue. In the raw-materials segment, PDRN and recombinant collagen are gradually becoming new growth drivers.